Theophylline and its intravenous (IV) prodrug aminophylline represent the oldest class of bronchodilator in clinical use, predating both beta-2 agonists and inhaled corticosteroids (ICS) by decades. Although now relegated to adjunctive roles in asthma and chronic obstructive pulmonary disease (COPD) by agents with superior safety profiles, theophylline retains a place in practice, particularly in low-resource settings, in severe refractory COPD, and in specific acute presentations, and its pharmacokinetic behavior remains among the most consequential and clinically perilous of any commonly prescribed pulmonary drug.
Theophylline is a methylxanthine alkaloid structurally related to caffeine and theobromine. Its bronchodilatory mechanism operates through two complementary pathways. The primary mechanism at therapeutic concentrations is inhibition of phosphodiesterase (PDE) enzymes, specifically PDE3 (phosphodiesterase 3) and PDE4 (phosphodiesterase 4), in airway smooth muscle (ASM) and inflammatory cells. PDE3 and PDE4 are the isoforms responsible for degrading cyclic AMP (cAMP) in these target cells; inhibition of PDE increases intracellular cAMP concentrations, activating protein kinase A (PKA), which phosphorylates myosin light chain kinase and reduces ASM contractility, producing bronchodilation. PDE4 inhibition in inflammatory cells reduces transcription of pro-inflammatory cytokines and inhibits mast cell degranulation, providing a modest anti-inflammatory effect that is separate from and additive to the bronchodilatory benefit.1
The second mechanism is non-competitive antagonism of adenosine receptors, primarily A1 (adenosine receptor subtype 1) and A2 (adenosine receptor subtype 2) subtypes, at therapeutic and toxic concentrations. Adenosine is a potent bronchoconstrictor acting through A1 receptors on ASM; it also promotes bronchoconstriction indirectly by triggering mast cell degranulation via A2B (adenosine receptor subtype 2B) receptors. Theophylline blockade of A1 receptors on ASM contributes to bronchodilation, and blockade of A2B receptors reduces mast cell histamine release. However, adenosine receptor antagonism at higher theophylline concentrations also produces the cardiac and central nervous system (CNS) toxicities that define theophylline's dangerous side effect profile: tachycardia and arrhythmias via adenosine A1 blockade in the sinoatrial (SA) and atrioventricular (AV) nodes, and CNS stimulation via A1 blockade in the brain contributing to anxiety, insomnia, and at toxic concentrations, seizures.1
Theophylline's pharmacokinetics are characterized by a narrow therapeutic index and dose-dependent, non-linear elimination that makes safe use difficult without serum level monitoring. At low serum concentrations, theophylline follows first-order elimination kinetics, with clearance proportional to concentration. However, as concentrations approach and exceed the therapeutic range of 10–20 micrograms per milliliter (mcg/mL), hepatic metabolism becomes saturated and elimination shifts toward Michaelis-Menten (zero-order or saturable) kinetics. The practical consequence is that a proportionally small increase in dose can produce a disproportionately large increase in serum concentration, and serum levels can escalate rapidly and unpredictably once saturation is reached. This is the pharmacokinetic basis for the clinical observation that theophylline toxicity often appears to develop suddenly, even in a patient who has been stable on a fixed dose for extended periods, when an intercurrent change in clearance tips the system past the saturation point.2
The therapeutic serum concentration range of 10–20 mcg/mL represents a pragmatic balance between efficacy and toxicity. Bronchodilatory benefit increases progressively across this range, but significant toxicity becomes probable above 20 mcg/mL and life-threatening toxicity (seizures, ventricular arrhythmias) is common above 40 mcg/mL. Many clinicians now target the lower portion of the traditional range (8–12 mcg/mL) to reduce toxicity risk, accepting modest reduction in peak efficacy, particularly in COPD maintenance where the goal is sustained bronchodilation rather than maximum acute effect. Aminophylline, the ethylenediamine salt of theophylline, contains 79–86% theophylline by weight and is the formulation used for IV administration; doses are calculated by weight of aminophylline but monitoring uses theophylline serum concentrations. Loading doses of aminophylline must account for the patient's existing theophylline concentration if any prior dosing has occurred, to avoid inadvertent overdose.2
Check steady-state trough levels after at least 48 hours on a stable dose. Draw levels 4–6 hours after an oral dose of a sustained-release preparation. Target 10–20 mcg/mL (many clinicians target 8–12 mcg/mL to reduce risk). Any change in smoking status, new interacting drug, intercurrent illness (especially hepatic or cardiac), or significant change in diet requires a repeat level within days. Never assume a previously stable patient remains stable when clinical circumstances change.
Theophylline toxicity is among the most clinically dangerous of any bronchodilator adverse effect profile because it affects multiple organ systems simultaneously, has a narrow margin between therapeutic and toxic concentrations, and is complicated by a pharmacokinetic interaction network that can dramatically and unpredictably alter serum levels through changes in smoking behavior, co-medications, and common illnesses. Every prescriber who uses theophylline must be facile with the specific toxicity manifestations and the interaction mechanisms that precipitate them.
Gastrointestinal (GI) toxicity is the earliest and most common manifestation of theophylline excess and frequently serves as the clinical warning sign that serum levels are rising toward the dangerous range. Nausea, vomiting, and abdominal cramping appear at serum concentrations in the range of 15–25 mcg/mL and are attributable to both local gastric irritation from direct mucosal contact with theophylline and to central emetic stimulation via adenosine receptor antagonism in the CNS (central nervous system). Diarrhea may accompany nausea and vomiting. GI symptoms are unreliable as a toxicity threshold marker in patients with chronic theophylline toxicity, in whom some degree of GI tolerance develops; conversely, in acute overdose, severe GI symptoms can precede or accompany life-threatening cardiac and CNS effects with minimal delay.3
Cardiac toxicity is the most immediately dangerous manifestation of theophylline excess. Sinus tachycardia appears early, driven by adenosine A1 (adenosine receptor subtype 1) receptor antagonism at the SA (sinoatrial) node combined with increased catecholamine release stimulated by theophylline. At serum concentrations above 20–25 mcg/mL, supraventricular tachycardias, including atrial fibrillation (AF) and multifocal atrial tachycardia, can appear; multifocal atrial tachycardia is particularly associated with theophylline toxicity in the setting of underlying lung disease. At concentrations above 35–40 mcg/mL, ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation (VF) can occur, particularly in patients with pre-existing cardiac disease, hypoxia, or electrolyte abnormalities. The arrhythmogenic risk is compounded by theophylline-induced hypokalemia, which occurs because theophylline stimulates epinephrine release and the resulting beta-2 adrenergic receptor activation drives potassium into cells, reducing serum potassium and lowering the threshold for ventricular arrhythmias.3
Neurological toxicity ranges from anxiety, tremor, and insomnia at mildly elevated concentrations to headache and agitation at moderate excess, and culminates in generalized tonic-clonic seizures at toxic concentrations. Theophylline-induced seizures are particularly dangerous because they are frequently refractory to standard anticonvulsant therapy, may be the first clinical manifestation of toxicity in some patients (particularly those with acute rather than chronic overdose), and carry a high mortality when they occur. The mechanism involves both adenosine A1 receptor antagonism in the CNS (normally adenosine is inhibitory in the brain and reduces neuronal excitability) and theophylline-mediated catecholamine release. In chronic theophylline toxicity, seizures may occur at lower serum concentrations than in acute overdose, because sustained receptor occupancy lowers the seizure threshold further.3
Theophylline is metabolized primarily by the hepatic cytochrome P450 (CYP) 1A2 isoenzyme, with minor contributions from CYP3A4 (cytochrome P450 3A4) and CYP2E1 (cytochrome P450 2E1). This creates a clinically critical drug-drug and drug-environment interaction network. Cigarette smoking is the most quantitatively significant inducer of CYP1A2 (cytochrome P450 1A2): smokers require theophylline doses approximately 50–60% higher than non-smokers to achieve equivalent serum concentrations, because polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2 expression. A patient who smokes and achieves stable therapeutic theophylline levels at a given dose will develop theophylline toxicity if they abruptly stop smoking, because CYP1A2 induction diminishes over 1–2 weeks and clearance falls dramatically while the dose remains unchanged. This is a recurring and preventable cause of theophylline toxicity that every clinician managing COPD (chronic obstructive pulmonary disease) must anticipate.4
Among drug interactions, fluoroquinolone antibiotics, particularly ciprofloxacin, are the most dangerous CYP1A2 inhibitors in routine clinical practice. Ciprofloxacin reduces theophylline clearance by approximately 30–50%, producing a corresponding rise in serum concentrations that can precipitate toxicity within days of starting the antibiotic. Erythromycin and other macrolide antibiotics inhibit CYP3A4 and reduce theophylline clearance by approximately 25–35%. Cimetidine, an H2 (histamine receptor subtype 2)-receptor antagonist, inhibits both CYP1A2 and CYP3A4 and can increase theophylline levels by 30–70%; it has largely been replaced by proton pump inhibitors, which do not share this interaction, but remains in use as an over-the-counter agent. Rifampin is a potent inducer of both CYP1A2 and CYP3A4 and can reduce theophylline serum concentrations by 50–75%, requiring substantial dose increases during co-administration and careful monitoring after rifampin discontinuation.4
Additional factors that reduce theophylline clearance and increase toxicity risk include congestive heart failure (CHF) through reduced hepatic blood flow and consequently impaired first-pass and systemic metabolism, hepatic cirrhosis through reduced functional hepatocyte mass, older age through progressive decline in CYP1A2 activity, and febrile viral illnesses which transiently reduce CYP1A2 activity through interferon-mediated CYP suppression. In acute theophylline overdose management, activated charcoal administered orally or via nasogastric tube remains the primary intervention for GI decontamination, and multi-dose activated charcoal is effective in enhancing theophylline elimination by interrupting enterohepatic recirculation. Hemodialysis is highly effective at removing theophylline and is indicated for severe toxicity with serum concentrations above 90 mcg/mL in acute overdose or above 40–60 mcg/mL in chronic toxicity, or at any concentration in a patient with life-threatening arrhythmia or refractory seizures.3
CYP1A2 inducers (reduce theophylline levels — dose increase needed): cigarette smoking (50–60% increase required), rifampin (50–75% reduction in levels), carbamazepine, phenytoin, barbiturates.
CYP1A2/CYP3A4 inhibitors (increase theophylline levels — toxicity risk): ciprofloxacin (30–50% level increase), erythromycin/clarithromycin (25–35%), cimetidine (30–70%), fluvoxamine (largest inhibitor; up to 3-fold increase), mexiletine, propafenone.
Physiological reducers of clearance (toxicity risk without dose change): smoking cessation, CHF decompensation, new hepatic disease, febrile viral illness, advanced age.
Leukotrienes are lipid mediators derived from arachidonic acid (AA) through the 5-lipoxygenase (5-LOX) pathway and play a central role in the pathophysiology of asthma, allergic rhinitis, and aspirin-exacerbated respiratory disease (AERD). Unlike the prostaglandin and thromboxane arms of arachidonic acid metabolism, which are governed by cyclooxygenase (COX) enzymes, the leukotriene arm is governed by 5-LOX and produces mediators whose principal targets are airways and inflammatory cells. The pharmacological interruption of this pathway, at either the receptor level (leukotriene receptor antagonists, LTRAs) or the synthetic enzyme level (zileuton, a 5-LOX inhibitor), represents a clinically meaningful strategy for asthma control and AERD management.
Arachidonic acid is released from cell membrane phospholipids by phospholipase A2 (PLA2) in response to inflammatory stimuli including allergen-IgE crosslinking on mast cells and basophils, mechanical stress, and cytokine signaling. Once liberated, AA can enter the COX pathway to generate prostaglandins and thromboxanes, or the 5-LOX pathway to generate leukotrienes. The 5-LOX pathway is initiated by 5-LOX, which acts in concert with the 5-LOX-activating protein (FLAP) anchored to the nuclear membrane, converting AA first to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and then to the unstable epoxide leukotriene A4 (LTA4). LTA4 is a branch point: it is either hydrolyzed by LTA4 hydrolase to leukotriene B4 (LTB4), or it undergoes conjugation with glutathione by LTC4 synthase to form leukotriene C4 (LTC4).5
LTB4 is a potent neutrophil chemoattractant acting through BLT1 (leukotriene B4 receptor 1) receptors on neutrophils and BLT2 (leukotriene B4 receptor 2) receptors on mast cells and eosinophils. LTB4 is the dominant leukotriene driving neutrophilic airway inflammation and is particularly relevant in COPD (chronic obstructive pulmonary disease), severe asthma with neutrophilic phenotype, and bronchiectasis. LTB4 also promotes CD4 (cluster of differentiation 4, helper T cell marker; CD4+) and CD8 (cluster of differentiation 8, cytotoxic T cell marker; CD8+) T lymphocyte recruitment to the airways. LTC4 produced in mast cells and eosinophils is exported from the cell and sequentially cleaved by extracellular gamma-glutamyl transpeptidase and dipeptidase to produce leukotriene D4 (LTD4) and leukotriene E4 (LTE4), respectively. LTC4, LTD4, and LTE4 together constitute the cysteinyl leukotrienes (CysLTs), formerly known as slow-reacting substances of anaphylaxis (SRS-A), a designation that reflects their historical identification as potent bronchoconstrictor mediators before their chemical structure was elucidated.5
CysLTs exert their pulmonary effects principally through the CysLT1 receptor, which is highly expressed on airway smooth muscle (ASM), bronchial epithelium, eosinophils, and mast cells. LTD4 is the most potent CysLT1 agonist, followed by LTC4 and LTE4. CysLT1 activation in ASM couples through Gq protein to phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG); IP3 triggers calcium release from the sarcoplasmic reticulum, producing ASM contraction. CysLTs are approximately 1000-fold more potent than histamine as bronchoconstrictors on a molar basis and their bronchoconstrictor effect is prolonged and resistant to beta-2 agonist-mediated reversal, which partly explains the incomplete response of some asthma attacks to short-acting beta-2 agonist (SABA) monotherapy. In addition to bronchoconstriction, CysLT1 activation drives airway edema through increased vascular permeability, stimulates goblet cell mucus secretion, enhances eosinophil adhesion and survival in the airway mucosa, and promotes subepithelial fibrosis through TGF-beta (transforming growth factor-beta) induction.6
The CysLT2 receptor has a distinct tissue distribution, being expressed primarily in cardiac tissue, adrenal gland, and lung macrophages. CysLT2 activation mediates vascular permeability effects and is not a primary bronchodilatory target; available LTRAs do not block CysLT2. The differential receptor expression pattern explains why montelukast and zafirlukast, which are selective CysLT1 antagonists, do not fully suppress all leukotriene-mediated effects in the airway but nonetheless produce clinically meaningful bronchodilation, reduction in airway hyperresponsiveness, and attenuation of the late-phase allergic response. The incomplete suppression of all leukotriene effects by CysLT1-selective antagonism is also one reason why LTRAs are considered add-on rather than monotherapy agents in moderate-to-severe asthma, where ICS (inhaled corticosteroids) remain the foundation of inflammatory control.6
Asthma: CysLTs are generated by mast cells during allergen challenge and drive bronchoconstriction, airway edema, and eosinophil recruitment. They are responsible for both the early-phase response (onset minutes after allergen exposure, mediated by immediate mast cell degranulation) and contribute to the late-phase response (4–8 hours post-exposure). LTRAs attenuate both phases. AERD (aspirin-exacerbated respiratory disease): COX-1 inhibition by aspirin diverts AA from prostaglandins toward the 5-LOX pathway, producing a surge in CysLT synthesis that is the pharmacological basis for aspirin and NSAID (non-steroidal anti-inflammatory drug) sensitivity. Allergic rhinitis: LTD4 drives nasal mucosal edema and congestion; LTRAs are effective for combined asthma-rhinitis management.
The leukotriene receptor antagonists (LTRAs) montelukast and zafirlukast, and the 5-lipoxygenase (5-LOX) inhibitor zileuton, constitute the leukotriene modifier drug class. They share the pharmacological target of the leukotriene pathway but differ substantially in their mechanism of action, adverse effect profiles, drug interaction burden, and convenience of use. Understanding these differences is essential for selecting the appropriate agent and for counseling patients on the specific risks associated with each drug, particularly the neuropsychiatric risks of montelukast that now carry a boxed warning.
Montelukast (Singulair) is a selective, competitive CysLT1 (cysteinyl leukotriene receptor 1) antagonist that blocks the binding of LTC4 (leukotriene C4), LTD4 (leukotriene D4), and LTE4 (leukotriene E4) at the CysLT1 receptor on airway smooth muscle and inflammatory cells. It is administered orally once daily in the evening (10 mg in adults; 5 mg chewable in children aged 6–14; 4 mg granules in children aged 2–5), and the evening dosing convention reflects the circadian rhythm of leukotriene production and the nocturnal worsening of asthma symptoms that LTRAs can partially ameliorate. Montelukast is nearly completely absorbed after oral administration, is highly protein-bound (greater than 99%), and is hepatically metabolized primarily by CYP3A4 (cytochrome P450 3A4) and CYP2C8 (cytochrome P450 2C8) with subsequent biliary excretion. Its approved indications include chronic asthma prophylaxis (not acute relief), exercise-induced bronchoconstriction (EIB), seasonal and perennial allergic rhinitis, and AERD (aspirin-exacerbated respiratory disease) as part of aspirin desensitization protocol management.6
The FDA (Food and Drug Administration) issued a boxed warning for montelukast in March 2020 regarding serious neuropsychiatric events, including agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (suicidality), and tremor. These events have been reported in patients across all age groups, including adults, adolescents, and children as young as 2 years. The neuropsychiatric mechanism is not fully elucidated but is thought to involve montelukast or its metabolite passage across the blood-brain barrier (BBB) and CysLT1 receptor blockade in the CNS (central nervous system), where CysLT1 receptors are expressed and appear to play a role in regulating neuroinflammatory signaling. As a result of the boxed warning, the FDA recommends that for patients with mild asthma or allergic rhinitis, the potential benefits of montelukast must be carefully weighed against the neuropsychiatric risks; for these milder indications, other therapies should be considered first. Montelukast remains appropriate for patients whose disease severity or co-morbid allergic rhinitis-asthma phenotype makes it a clinically justified choice, but patients and caregivers must be counseled on the neuropsychiatric risks and instructed to discontinue and contact their prescriber if such symptoms develop.77
Zafirlukast (Accolate) is also a selective CysLT1 antagonist but differs from montelukast in several clinically important pharmacological characteristics. Zafirlukast is dosed twice daily (20 mg twice daily in adults), must be taken on an empty stomach (food reduces bioavailability by approximately 40%), and is metabolized primarily by CYP2C9 (cytochrome P450 2C9) rather than CYP3A4. This CYP2C9 dependence makes zafirlukast susceptible to interactions with CYP2C9 inhibitors (fluconazole, amiodarone, fluvastatin) which can increase zafirlukast plasma concentrations, and CYP2C9 inducers (rifampin, carbamazepine) which reduce them. Of particular clinical consequence, zafirlukast itself inhibits CYP2C9 and CYP3A4 at clinical concentrations, which increases plasma concentrations of co-administered drugs metabolized by these enzymes, including warfarin (INR [international normalized ratio] monitoring is required when zafirlukast is added to warfarin therapy), certain statins, and cyclosporine. Zafirlukast is associated with a rare Churg-Strauss syndrome-like vasculitis that has been reported upon steroid dose reduction in patients on zafirlukast, though a causal relationship versus unmasking of pre-existing disease remains debated.8
Zileuton (Zyflo, Zyflo CR) occupies a mechanistically distinct position within the leukotriene modifier class: rather than blocking leukotriene receptors, it inhibits 5-LOX directly, reducing synthesis of all leukotrienes including both LTB4 (leukotriene B4) and the cysteinyl leukotrienes. Because it acts upstream of the receptor, zileuton suppresses a broader spectrum of leukotriene effects than selective CysLT1 antagonists, including LTB4-driven neutrophilic inflammation. Zileuton is metabolized by CYP1A2 (cytochrome P450 1A2), CYP2C9, and CYP3A4, and it inhibits CYP1A2, making it susceptible to CYP1A2-mediated interactions and capable of increasing serum levels of CYP1A2 substrates including theophylline. Co-administration of zileuton and theophylline requires theophylline dose reduction (by approximately 50%) and careful serum level monitoring, because zileuton inhibition of CYP1A2 can double theophylline concentrations within days.9 Zileuton is approved for the prevention and treatment of asthma in adults and children aged 12 and older. It requires monitoring of liver function tests (LFTs) at baseline and periodically thereafter (monthly for the first 3 months, every 2–3 months for the remainder of the first year, and periodically thereafter) because it causes hepatocellular injury in a small percentage of patients; it is contraindicated in patients with active hepatic disease or liver enzyme elevations above 3 times the upper limit of normal (ULN).
In the context of asthma step therapy, LTRAs occupy the role of alternative or add-on controller agents rather than first-line anti-inflammatory agents. At GINA (Global Initiative for Asthma) Step 2, LTRAs are an alternative to low-dose ICS (inhaled corticosteroids) for patients who cannot or will not use inhaled therapy, but they are consistently less effective than ICS at reducing exacerbations and improving lung function; the Price et al. NEJM 2011 pragmatic trial established that LTRA (leukotriene receptor antagonist) monotherapy is inferior to ICS for most asthma patients at step 2. At Step 3 and above, LTRAs serve as add-on agents to ICS or ICS/LABA (long-acting beta-2 agonist) combinations, where they provide incremental benefit in exacerbation reduction and symptom control through pharmacological complementarity with inhaled therapy, particularly in patients with concurrent allergic rhinitis and in those with aspirin sensitivity. Exercise-induced bronchoconstriction is a specific niche where LTRAs are particularly effective, suppressing EIB (exercise-induced bronchoconstriction) when taken prior to exercise and providing benefit in patients who cannot use pre-exercise SABA (short-acting beta-2 agonist) reliably or who experience refractory EIB despite SABA pre-treatment.6
Discuss neuropsychiatric risks with every patient and caregiver before initiating montelukast, regardless of age. Evaluate benefit-risk carefully for mild asthma and allergic rhinitis — for these indications other therapies should be tried first. If neuropsychiatric symptoms develop (sleep disturbance, behavioral change, depression, suicidal ideation, aggression), discontinue montelukast and contact the prescriber. Document the counseling and the patient's informed decision in the medical record. The warning does not mean montelukast is contraindicated for all patients; it means that for mild disease, the risk may outweigh the benefit when alternatives exist.
Mast cell stabilizers and AERD (aspirin-exacerbated respiratory disease) occupy opposite ends of the pharmacological spectrum in this module: cromolyn and nedocromil are preventive agents whose clinical relevance has substantially diminished in the era of ICS (inhaled corticosteroids) and biological agents, while AERD is a pharmacologically and immunologically complex syndrome whose pathophysiology is rooted in the same leukotriene pathway described in Section 3 and whose management requires both pharmacological and procedural intervention.
Cromolyn sodium (Intal) and nedocromil sodium (Tilade) are mast cell stabilizers that prevent the release of preformed mediators from sensitized mast cells in response to allergen or other stimuli. The mechanism is not fully established but appears to involve blockade of chloride channels on the mast cell surface, which prevents the calcium influx and membrane depolarization required for exocytosis of secretory granules. Cromolyn also inhibits sensory nerve activation in the airway, suppressing the neurogenic component of bronchoconstriction. Neither agent has meaningful bronchodilatory activity; they are strictly prophylactic and must be used before allergen exposure or exercise to be effective; they do not relieve established bronchoconstriction. Cromolyn is available as an inhaled solution for nebulizer use (4 mg four times daily), as a nasal spray for allergic rhinitis, and as an oral formulation for GI (gastrointestinal) mastocytosis. Nedocromil is available as a pMDI (pressurized metered-dose inhaler) for inhalation. Both agents have excellent safety profiles with virtually no systemic adverse effects, because systemic absorption is negligible; the principal adverse effect is local oropharyngeal irritation from the inhaled preparations.10
The clinical role of mast cell stabilizers in asthma has contracted dramatically since the 1990s as evidence for ICS superiority has accumulated. Multiple controlled trials have demonstrated that low-dose ICS provides greater asthma control, greater reduction in airway hyperresponsiveness, and superior exacerbation prevention compared with cromolyn or nedocromil at equivalent dosing frequency. Current GINA (Global Initiative for Asthma) guidelines do not include mast cell stabilizers as preferred or alternative agents at any step of the asthma treatment ladder for adults; they retain a very limited role in pediatric asthma in settings where ICS are poorly tolerated or in specific allergen challenge prevention protocols. The four-times-daily dosing requirement of inhaled cromolyn and the consequent adherence challenges further limited its practical utility even in the era before ICS became standard of care.10
AERD, also known as Samter's triad or aspirin-sensitive asthma, is a clinical syndrome defined by three features: chronic rhinosinusitis with nasal polyposis, asthma (typically moderate to severe), and hypersensitivity reactions to aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 (cyclooxygenase-1). The hypersensitivity reaction is not IgE-mediated and therefore does not represent a true allergic reaction in the immunological sense; rather, it is a pharmacological reaction mediated by the metabolic consequences of COX-1 inhibition. The pathophysiological mechanism is as follows: in AERD patients, there is constitutive overproduction of cysteinyl leukotrienes by mast cells and eosinophils in the airway mucosa, driven in part by reduced prostaglandin E2 (PGE2) synthesis. PGE2 normally exerts a restraining, anti-inflammatory influence on mast cell and eosinophil 5-LOX activity through EP2 (prostaglandin E2 receptor subtype 2) receptors; when COX-1 is inhibited by aspirin or NSAIDs, PGE2 synthesis falls abruptly, this restraint is lost, and arachidonic acid (AA) is shunted preferentially into the 5-LOX pathway. The resulting surge in CysLT production triggers bronchoconstriction, nasal congestion, flushing, and urticaria within 30–180 minutes of NSAID (non-steroidal anti-inflammatory drug) ingestion.11
The prevalence of AERD in the asthma population is approximately 7% in adults and higher (up to 14–20%) in patients with severe asthma and nasal polyposis.12 All COX-1-inhibiting NSAIDs share cross-reactivity: patients sensitive to aspirin will react to ibuprofen, naproxen, indomethacin, ketorolac, and other COX-1 inhibitors at anti-inflammatory doses. COX-2 (cyclooxygenase-2)-selective inhibitors (celecoxib) are generally tolerated in AERD at standard doses, though caution is warranted with higher doses or in patients with very severe AERD, as COX-2 inhibitors retain some residual COX-1 activity at high concentrations. Acetaminophen (paracetamol) at standard doses (less than 1 gram per dose) is generally safe in AERD, although at higher doses it inhibits COX-1 sufficiently to trigger reactions in some sensitive patients. The management of AERD includes strict NSAID avoidance, aggressive topical nasal corticosteroid therapy, and sinus surgery for refractory polyposis. LTRAs (leukotriene receptor antagonists) are specifically indicated and clinically effective in AERD because they target the CysLT1 receptor that is directly activated by the leukotriene surge triggered by COX-1 inhibition; montelukast reduces both the severity of baseline disease and the severity of aspirin-provoked reactions.11
Aspirin desensitization is a procedure available at specialized centers for AERD patients who require aspirin or NSAID therapy (for example, patients with AERD who also have ischemic heart disease requiring aspirin) or as a disease-modifying intervention in selected patients with severe refractory nasal polyposis. The procedure involves supervised, graded oral aspirin challenge starting at very low doses (typically 30–60 mg) in a controlled setting with resuscitation equipment available, incrementally increasing the dose over 1–3 days until tolerance to full-dose aspirin (typically 325–650 mg twice daily) is achieved. The mechanism of desensitization is not fully understood but involves downregulation of CysLT1 receptors, desensitization of mast cell and eosinophil responsiveness to CysLT1 signaling, and possible upregulation of the anti-inflammatory EP2 prostaglandin receptor. Desensitization must be maintained with continuous aspirin use, because the tolerant state reverses within days of aspirin discontinuation. In observational studies, successful aspirin desensitization has been associated with significant reductions in nasal polyp recurrence, sinus surgery frequency, oral corticosteroid (OCS) requirements, and asthma exacerbation rates, though prospective controlled data remain limited.11
Triad: Chronic rhinosinusitis with nasal polyposis + asthma (typically moderate–severe) + hypersensitivity to aspirin and COX-1-inhibiting NSAIDs.
Mechanism: COX-1 inhibition → reduced PGE2 → loss of PGE2/EP2 restraint on mast cell and eosinophil 5-LOX activity → AA shunted to 5-LOX → CysLT surge → bronchoconstriction, nasal symptoms, urticaria within 30–180 minutes. Reaction is pharmacological, not IgE-mediated.
Safe analgesics: acetaminophen at doses below 1 g; celecoxib at standard doses (with caution).
Management: NSAID avoidance; nasal corticosteroids; LTRAs (montelukast); sinus surgery for polyposis; aspirin desensitization for selected patients at specialized centers.
Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–906.
doi:10.1164/rccm.201302-0388PPHendeles L, Weinberger M. Theophylline: a state of the art review. Pharmacotherapy. 1983;3(1):2–44.
doi:10.1002/j.1875-9114.1983.tb04531.xShannon M. Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med. 1999;159(9):989–994.
doi:10.1001/archinte.159.9.989Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36(6):425–438.
doi:10.2165/00003088-199936060-00004Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220(4597):568–575.
doi:10.1126/science.6301011Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340(3):197–206.
doi:10.1056/NEJM199901213400306Clarridge K, Chin S, Eworuke E, Seymour S. A boxed warning for montelukast: the FDA perspective. J Allergy Clin Immunol Pract. 2021;9(7):2638–2641.
doi:10.1016/j.jaip.2021.02.057Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279(6):455–457.
doi:10.1001/jama.279.6.455Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(Suppl 2):77–83.
doi:10.2165/00003088-199500292-00011Bernstein IL. Cromolyn sodium in the treatment of asthma: coming of age in the United States. J Allergy Clin Immunol. 1985;76(2 Pt 2):381–388.
doi:10.1016/0091-6749(85)90658-XStevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773–786.
doi:10.1016/j.jaci.2006.07.024Morales DR, Guthrie B, Lipworth BJ, Jackson C, Donnan PT, Santiago VH. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015;70(7):828–835.
doi:10.1111/all.12629